查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1977903

全球重組蛋白治療藥物開發和生產組織（CDMO）市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Recombinant Protein Therapeutics CDMO Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計重組蛋白療法 CDMO 市場將從 2025 年的 313.5 億美元成長到 2034 年的 1,036.5 億美元，2026 年至 2034 年的複合年成長率為 14.21%。

受生物製藥和生物相似藥需求不斷成長的推動，全球重組蛋白療法（CDMO）市場正經歷強勁成長。製藥公司將生產外包給CDMO，以降低成本並縮短產品上市時間。慢性病盛行率的上升也顯著增加了對蛋白質療法的需求。

關鍵成長要素包括生物製程技術的進步、生物技術產業的擴張以及生物製藥監管核准的增加。單株抗體和標靶治療的日益普及也增強了市場需求。此外，合約研發生產機構（CDMO）透過提供可擴展的生產能力，吸引了新興生物技術公司和成熟的製藥公司。

展望未來，細胞株開發和連續生產過程的創新可望惠及市場。生物製劑產品線的拓展和生物製藥研發投入的增加將進一步推動市場成長。新興市場預計將在擴大產能和確保永續的長期成長方面發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球重組蛋白治療藥物開發與生產組織（CDMO）市場：依類型分類

  • 市場分析、洞察與預測
  • 生長激素
  • 干擾素
  • 疫苗
  • 免疫促效劑
  • 其他

第5章：全球重組蛋白治療藥物開發與生產組織（CDMO）市場：依來源分類

  • 市場分析、洞察與預測
  • 哺乳動物系統
  • 微生物系統
  • 其他

第6章：全球重組蛋白治療藥物（CDMO）市場：依適應症分類

  • 市場分析、洞察與預測
  • 腫瘤學
  • 感染疾病
  • 免疫疾病
  • 代謝性疾病
  • 血液疾病
  • 其他

第7章 全球重組蛋白治療藥物開發與生產組織（CDMO）市場：依服務類型分類

  • 市場分析、洞察與預測
  • 契約製造
  • 合約開發

第8章：全球重組蛋白治療藥物開發與生產組織（CDMO）市場：依最終用途分類

  • 市場分析、洞察與預測
  • 製藥公司
  • 生技公司
  • 其他

第9章 全球重組蛋白治療藥物研發生產機構（CDMO）市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Richter-Helm BioLogics
    • Lonza
    • Catalent Inc
    • Fujifilm Diosynth Biotechnologies
    • WuXi Biologics
    • Curia Global Inc
    • Batavia Biosciences BV
    • HALIX BV
    • Biovian
    • Enzene Biosciences Ltd
簡介目錄
Product Code: VMR112113789

The Recombinant Protein Therapeutics CDMO Market size is expected to reach USD 103.65 Billion in 2034 from USD 31.35 Billion (2025) growing at a CAGR of 14.21% during 2026-2034.

The Global Recombinant Protein Therapeutics CDMO Market is experiencing strong growth driven by increasing demand for biologics and biosimilars. Pharmaceutical companies are outsourcing manufacturing to contract development and manufacturing organizations (CDMOs) to reduce costs and accelerate time-to-market. Rising prevalence of chronic diseases has significantly increased demand for protein-based therapeutics.

Major growth drivers include advancements in bioprocessing technologies, expanding biotechnology sector, and increasing regulatory approvals for biologic drugs. The growing focus on monoclonal antibodies and targeted therapies has strengthened market demand. Additionally, CDMOs offer scalable production capabilities, attracting both emerging biotech firms and established pharmaceutical companies.

Looking forward, the market is expected to benefit from innovations in cell line development and continuous manufacturing processes. Expansion of biologics pipelines and increasing investments in biopharmaceutical research will further drive growth. Emerging markets are likely to play a crucial role in expanding manufacturing capacities, ensuring sustained long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Growth Hormones
  • Interferons
  • Vaccines
  • Immunostimulating Agents
  • Others

By Source

  • Mammalian Systems
  • Microbial Systems
  • Others

By Indication

  • Oncology
  • Infectious Diseases
  • Immunological Disorders
  • Metabolic Disorders
  • Haematological Disorders
  • Others

By Service Type

  • Contract Manufacturing
  • Contract Development

By End Use

  • Pharmaceutical Companies
  • Biotech Companies
  • Others

COMPANIES PROFILED

  • RichterHelm BioLogics, Lonza, Catalent Inc, Fujifilm Diosynth Biotechnologies, WuXi Biologics, Curia Global Inc, Batavia Biosciences BV, HALIX BV, Biovian, Enzene Biosciences Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Growth Hormones Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Interferons Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Immunostimulating Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY SOURCE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Source
  • 5.2. Mammalian Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Microbial Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY INDICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Indication
  • 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Immunological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Haematological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Service Type
  • 7.2. Contract Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Contract Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY END USE 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast End Use
  • 8.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY REGION 2022-2034(USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Type
    • 9.2.2 By Source
    • 9.2.3 By Indication
    • 9.2.4 By Service Type
    • 9.2.5 By End Use
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Type
    • 9.3.2 By Source
    • 9.3.3 By Indication
    • 9.3.4 By Service Type
    • 9.3.5 By End Use
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Type
    • 9.4.2 By Source
    • 9.4.3 By Indication
    • 9.4.4 By Service Type
    • 9.4.5 By End Use
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Type
    • 9.5.2 By Source
    • 9.5.3 By Indication
    • 9.5.4 By Service Type
    • 9.5.5 By End Use
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Type
    • 9.6.2 By Source
    • 9.6.3 By Indication
    • 9.6.4 By Service Type
    • 9.6.5 By End Use
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Richter-Helm BioLogics
    • 11.2.2 Lonza
    • 11.2.3 Catalent Inc
    • 11.2.4 Fujifilm Diosynth Biotechnologies
    • 11.2.5 WuXi Biologics
    • 11.2.6 Curia Global Inc
    • 11.2.7 Batavia Biosciences B.V
    • 11.2.8 HALIX B.V
    • 11.2.9 Biovian
    • 11.2.10 Enzene Biosciences Ltd